Printer Friendly

CBOE LISTS OPTIONS ON GENELABS TECHNOLOGIES, RIBI IMMUNOCHEM RESEARCH ON THURSDAY, JAN. 23; AUTOZONE, ORGANOGENESIS, ON MONDAY, JAN. 27

CBOE LISTS OPTIONS ON GENELABS TECHNOLOGIES, RIBI IMMUNOCHEM RESEARCH ON THURSDAY, JAN. 23; AUTOZONE, ORGANOGENESIS, ON MONDAY, JAN. 27
 CHICAGO, Jan. 22 /PRNewswire/ -- The Chicago Board Options Exchange (CBOE) today announced it will begin trading options on Genelabs Technoloigies, Inc. (ticker symbol GNLB; CBOE ticker symbol LBQ), and on Ribi ImmunoChem Research, Inc. (ticker symbol RIBI; CBOE ticker symbol LBQ), on Thursday, Jan. 23.
 Additionally, the exchange will begin trading options on AutoZone, Inc. (ticker symbol AZO), and on Organogenesis, Inc. (ticker symbol ORG), on Monday, Jan. 27.
 Genelabs Technologies, Inc., is located in Redwood City, Calif. The company and its subsidiaries combine advanced molecular and cellular engineering techniques with medicinal chemistry to develop products for the treatment and prevention of viral diseases and cancer, and viral diagnostic products.
 LBQ options will trade on the January expiration cycle, with introductory expirations in February, March, April and July. Initial strike prices have been set at 7-1/2, 10 and 12-1/2.
 Ribi ImmunoChem Research, Inc., is a Hamilton, Mont.-based company, engaged in the research, development and production of immunological agents, mainly adjuvants for use in treatment of cancer and infectious diseases. The company also manufactures and markets a line of research products.
 LBQ options will trade on the January expiration cycle, with introductory expirations in February, March, April and July. Initial strike prices have been set at 7-1/2, 10 and 12-1/2.
 Memphis, Tenn.-based AutoZone, Inc., sells automotive replacement parts, chemicals and accessories through its chain of 610 retail stores in 20 states, primarily in the U.S. Sunbelt.
 AZO options will trade on the March expiration cycle, with introductory expirations in February, March, June and September. Initial strike prices have been set at 55, 60, and 65.
 Headquartered in Cambridge, Mass., Organogenesis, Inc., is a company engaged in developing and fabricating living organ equivalents from human cells and tissue matrix molecules, to replace diseased human organs (Graftorgans) and for test organ systems (Testorgans).
 ORG options will trade on the January expiration cycle, with introductory expirations in February, March, April and July. Initial strike prices have been set at 20, 22-1/2 and 25.
 CBOE, regulated by the Securities and Exchange Commission, is the pioneer of listed options and the world's largest options marketplace.
 -0- 1/22/92
 /CONTACT: Patricia Campbell, 312-786-7927, or Bonnie Greenberg, 312-786-7393, both of CBOE/
 (GNLB) CO: Genelabs Technologies, Inc.; Ribi ImmunoChem Research, Inc.;
 AutoZone, Inc.; Organogenesis, Inc. ST: California, Montana, Tennessee, Massachusetts IN: MTC AUT SU:


GK -- NY074 -- 2371 01/22/92 13:56 EST
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jan 22, 1992
Words:422
Previous Article:GENERAL DATACOMM ANNOUNCES FIRST QUARTER RESULTS
Next Article:HEALTH IMAGES COMMENTS ON EARNINGS
Topics:


Related Articles
S.R. ONE WARRANT EXERCISE ADDS $1.57 MILLION TO RIBI IMMUNOCHEM BALANCE SHEET
PRECLINICAL TESTING INDICATES RIBI IMMUNOCHEM'S MPL(R) SIGNIFICANTLY PROTECTS HEART MUSCLE FROM REPERFUSION INJURY
CHICAGO BOARD OPTIONS EXCHANGE INITIATES TRADING IN OPTIONS FOR RIBI COMMON STOCK
TOXICITY OF ENDOTOXIN, A CAUSE OF SEPTIC SHOCK, IS ATTENUATED BY RIBI IMMUNOCHEM'S MPL IN HUMAN CLINICAL STUDY
RATIONALE FOR IMMUNIZATION WITH MPL(R) AGAINST SEPTIC SHOCK SUPPORTED BY NEW SCIENTIFIC DATA FROM RIBI IMMUNOCHEM
RIBI IMMUNOCHEM LICENSES MELACINE MELANOMA THERACCINE TO BIOMIRA INC. EXCLUSIVELY IN CANADA
RIBI, LEDERLE-PRAXIS BIOLOGICALS SIGN LETTER OF INTENT TO COMPLETE NEGOTIATION OF CO-EXCLUSIVE ADJUVANT LICENSE/SUPPLY AGREEMENT
RIBI IMMUNOCHEM ANNOUNCES PUBLIC OFFERING OF COMMON STOCK
2,250,000 SHARES OF RIBI IMMUNOCHEM COMMON STOCK OFFERED AT $6 PER SHARE
RIBI IMMUNOCHEM: WARRANT EXERCISE CONTRIBUTES $5.8 MILLION TO RIBI BALANCE SHEET

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters